Combining AMP vaccination with TCR T-cell therapies leads to improved and durable antitumor efficacy
Feb. 1, 2024
Amphiphile (AMP)-modification of peptide antigens and molecular adjuvants has been previously demonstrated to enhance lymphatic delivery and retention, resulting in potent expansion of cognate endogenous T-cell responses.